Halozyme Therapeutics, Inc. — Q3 2011 Form 10-Q
Reporting period: Three and nine months ended September 30, 2011. Halozyme is a biopharmaceutical company developing recombinant human enzymes, including its Enhanze delivery technology, and proprietary product candidates. The company relies substantially on collaborations and had limited product sales.
Financial performance and liquidity
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Total revenue | $22.94 million | $3.40 million | $53.68 million | $10.05 million |
| Operating income (loss) | $5.15 million | ($12.43 million) | ($1.41 million) | ($36.37 million) |
| Net income (loss) | $5.17 million | ($12.41 million) | ($1.35 million) | ($36.35 million) |
| Research and development expense | $13.51 million | $12.45 million | $42.65 million | $35.84 million |
| Selling, general and administrative expense | $4.26 million | $3.37 million | $12.24 million | $10.49 million |
| Net cash used in operating activities | Not provided for quarter | Not provided for quarter | $20.80 million | $38.01 million |
Q3 revenue included $17.9 million from releasing previously deferred Hylenex-related amounts after Baxter’s transition agreement ended Halozyme’s remaining performance obligations, plus a $3.0 million ViroPharma milestone. Thus, quarterly profit and revenue were materially affected by unusual recognition of deferred revenue and should not be read as a recurring operating run rate. Nine-month collaborative revenue also included $18.0 million in upfront fees from ViroPharma and Intrexon and $11.0 million in Roche, Baxter and ViroPharma milestones.
At September 30, cash and cash equivalents were $66.3 million, down from $83.3 million at December 31, 2010. Nine-month investing cash outflow was $0.27 million and financing inflow was $4.14 million, primarily from stock-option exercises. Current assets were $77.0 million and current liabilities $13.8 million; the filing reports no borrowings or other interest-bearing debt on the balance sheet. Total deferred revenue was $40.4 million, down from $58.1 million, largely reflecting recognition of Hylenex amounts. Management estimated 2011 net cash burn of $30–35 million and believed available cash would fund operations for at least 12 months.
Product sales were $1.16 million in Q3 and $1.49 million for the nine months. The filing does not present a meaningful gross-margin measure for the business; product-sales costs were small relative to revenue, while the company’s substantial R&D and corporate costs drove operating results.
Material changes and business developments
- Revenue rose sharply year over year, mainly because of collaboration upfront fees and milestones, and the one-time recognition of $17.9 million of deferred Hylenex-related revenue in Q3.
- R&D expense increased 19% for the nine months, principally due to clinical-trial and manufacturing activity; SG&A rose 16%. Management expected both R&D and SG&A to increase, including higher marketing costs for a planned Hylenex relaunch.
- Halozyme and Baxter terminated the Hylenex Partnership in January 2011. The FDA approved the data supporting reintroduction, and management expected Hylenex recombinant to return to market by year-end 2011. Baxter continued to provide fill-and-finish services under a separate agreement.
- New ViroPharma and Intrexon collaborations each included a $9 million upfront license fee. ViroPharma began a Phase 2 study of subcutaneous Cinryze with rHuPH20 and triggered a $3 million milestone in Q3.
- Pipeline updates included positive reported Phase 2 ultrafast-insulin results, ongoing PEGPH20 Phase 1 work and initiation of a Phase 1b/2 pancreatic-cancer study, and a September start to an HTI-501 proof-of-concept study. These are development-stage programs, not established product revenues.
Outlook, risks and contingencies
Management anticipated continued operating cash requirements and stated that revenues were not expected to fund operations for several years. It expected collaboration revenue to fluctuate with partner requests for services and API, milestone achievement and new agreements. The company had up to $39.8 million available under its shelf registration statement, but additional financing might be needed; availability and terms were uncertain, and equity financing could dilute shareholders.
Key risks include clinical-trial failure or delay, regulatory approval and market acceptance, reliance on partners and contract manufacturers, scaling up rHuPH20 production, and dependence on the rHuPH20 platform across multiple programs. Hylenex’s prior voluntary recall followed manufacturing noncompliance at Baxter; the planned relaunch remained dependent on manufacturing and commercial execution. Collaboration partners generally could terminate on 90 days’ notice. The filing also describes patent opposition in Europe and potential reimbursement, pricing, competition and product-liability risks. Management reported no material litigation expected to adversely affect the company; Baxter’s breach claims were discharged under the transition agreement.
Important facts for investors to verify
- Whether Hylenex recombinant was successfully relaunched by the stated year-end 2011 target, and whether manufacturing and supply arrangements supported sustained sales.
- How much future revenue and cash generation depends on milestone payments, collaboration accounting and partner-requested services, rather than recurring product sales or royalties.
- Clinical and regulatory progress for ultrafast insulin, PEGPH20, HTI-501 and partnered programs, including whether reported trial findings are confirmed in subsequent studies.
- Cash burn against management’s $30–35 million 2011 estimate, subsequent financing needs and potential dilution.
- Manufacturing scale-up and qualification risks, partner continuation of programs, and the status of the European patent opposition.